[go: up one dir, main page]

AU2001234690A1 - 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa - Google Patents

2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa

Info

Publication number
AU2001234690A1
AU2001234690A1 AU2001234690A AU3469001A AU2001234690A1 AU 2001234690 A1 AU2001234690 A1 AU 2001234690A1 AU 2001234690 A AU2001234690 A AU 2001234690A AU 3469001 A AU3469001 A AU 3469001A AU 2001234690 A1 AU2001234690 A1 AU 2001234690A1
Authority
AU
Australia
Prior art keywords
quinoxalone
quinolone
inhibitors
factor
quinoxalone inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234690A
Inventor
Robert Scarborough
Bing-Yan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Publication of AU2001234690A1 publication Critical patent/AU2001234690A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001234690A 2000-02-01 2001-02-01 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa Abandoned AU2001234690A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17938900P 2000-02-01 2000-02-01
US60179389 2000-02-01
US19172200P 2000-03-24 2000-03-24
US60191722 2000-03-24
PCT/US2001/003176 WO2001057021A2 (en) 2000-02-01 2001-02-01 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa

Publications (1)

Publication Number Publication Date
AU2001234690A1 true AU2001234690A1 (en) 2001-08-14

Family

ID=26875280

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001234690A Abandoned AU2001234690A1 (en) 2000-02-01 2001-02-01 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa

Country Status (4)

Country Link
US (1) US6777413B2 (en)
EP (1) EP1255741A2 (en)
AU (1) AU2001234690A1 (en)
WO (1) WO2001057021A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US6962926B2 (en) 2001-01-31 2005-11-08 Telik, Inc. Antagonist of MCP-1 function, and compositions and methods of use thereof
TWI245761B (en) 2001-03-01 2005-12-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
TWI236474B (en) 2001-04-03 2005-07-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
PT1569912E (en) 2002-12-03 2015-09-15 Pharmacyclics Llc 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
ES2524922T3 (en) 2005-05-10 2014-12-15 Intermune, Inc. Pyridone derivatives to modulate the stress-activated protein kinase system
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2009021965A2 (en) 2007-08-15 2009-02-19 Glaxo Group Limited Substituted quinoline derivatives as h1 receptor antagonists
ATE541841T1 (en) 2007-11-15 2012-02-15 Boehringer Ingelheim Int INHIBITORS OF REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5627574B2 (en) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド Compounds and methods for treating inflammatory and fibrotic diseases
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
JP6360878B2 (en) 2013-03-12 2018-07-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ DNA-PK inhibitor
SI3057953T1 (en) 2013-10-17 2018-12-31 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-(4,5'-bipyrimidin)-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
MX382781B (en) 2014-04-02 2025-03-13 Intermune Inc ANTI-FIBROTIC PYRIDINONES.
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN106573915B (en) 2014-08-01 2020-12-25 纽韦卢森公司 Compounds active against bromodomains
AR105911A1 (en) 2015-09-03 2017-11-22 Forma Therapeutics Inc FUSIONED BICYCLIC HDAC8 INHIBITORS [6,6]
AU2017335648B2 (en) 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475009A (en) * 1994-09-12 1995-12-12 Abbott Laboratories 1, 2-dialkoxyethanes as 5-lipoxygenase inhibitors
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
AU2074699A (en) 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
JP2002509925A (en) 1998-03-31 2002-04-02 ワーナー−ランバート・カンパニー Benzoxazinone / benzothiazinone as serine protease inhibitor
WO1999050254A1 (en) * 1998-03-31 1999-10-07 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
ATE268766T1 (en) 1999-07-16 2004-06-15 Bristol Myers Squibb Pharma Co NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa

Also Published As

Publication number Publication date
US6777413B2 (en) 2004-08-17
US20020058657A1 (en) 2002-05-16
WO2001057021A3 (en) 2002-02-14
EP1255741A2 (en) 2002-11-13
WO2001057021A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU2001234690A1 (en) 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa
AU2001249399A1 (en) Isoquinolone inhibitors of factor xa
AU2002214626A1 (en) Quaternary amines and related inhibitors of factor xa
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
AU4166400A (en) Alkenyl and alkynyl compounds as inhibitors of factor xa
AU2001234705A1 (en) Indalone and benzimidazolone inhibitors of factor xa
HUP0203289A3 (en) Benzamides and related inhibitors of factor xa
AU2001236605A1 (en) Indole and benzimidazole inhibitors of factor xa
ZA200306488B (en) Benzamides and related inhibitors of factor Xa.
AU2003301662A1 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
AU2002356762A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
AU2002254328A1 (en) Inhibitors and disassemblers of fibrillogenesis
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001249397A1 (en) Oxindole inhibitors of factor xa
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2001297648A1 (en) Substituted carboxamides as inhibitors of factor xa
AU2002256085A1 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002306624A1 (en) Heterocyclic analgesic compounds and methods of use thereof
AU2002303264A1 (en) Fused heterocyclic inhibitors of factor xa
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2001294824A1 (en) Piperazine based inhibitors of factor xa
AU2003251047A1 (en) Use of quinoline derivatives with anti-integrase effect and applications thereof
AU2001232809A1 (en) Gyrase inhibitors and uses thereof